Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

16.73 -0.41 (-2.39%)
Streaming Delayed Price Updated: 10:05 AM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tonix Pharmaceuticals Holding Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awaits FDA Decision on New Fibromyalgia Treatment
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands Leadership Team to Support TNX-102 SL Launch
Via Investor Brand Network
InvestorkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) COO to Present at NobleCon20 Emerging Growth Conference
Via Investor Brand Network
News headline image
Looking Into Tonix Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
(TNXP) - Analyzing Tonix Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) COO to Present at Winter 2024 Investor Summit
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Phase 3 Success for TNX-102 SL in Fibromyalgia Treatment
Via Investor Brand Network
Jessica Edgar Morris, COO of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), to Present at NobleCon20
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches Rapid-Relief Migraine Treatments for Urgent Needs
Via Investor Brand Network
News headline image
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
Via ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Promising Data on TNX-801 Vaccine for Mpox and Smallpox
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Submits NDA for Fibromyalgia Treatment and Advances Mpox Vaccine Development
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Kenya Medical Research Institute Partner on Phase I Trial for Mpox and Smallpox Vaccine TNX-801
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Promising Mpox Vaccine Data at World Vaccine Congress
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at BIO-Europe in Stockholm
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at ThinkEquity Conference
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Mpox Vaccine Research at World Vaccine Congress Europe 2024
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Receives First Payment from U.S. Defense Agency to Develop Broad-Spectrum Antiviral Agents
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Submits New Drug Application to FDA for TNX-102 SL for Fibromyalgia Treatment
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), X-Chem to Collaborate in Development of Broad-Spectrum Antivirals
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Why Tonix Pharmaceuticals (TNXP) Stock Is Moving ↗
Tonix Pharmaceuticals shares are trading higher by 8% during Tuesday's session. The company secured a $34 million DOD research collaboration contract with X-Chem. 
Via Benzinga
News headline image
AI Security, “Netflix of China”, Healthcare Breakthroughs, Pure Play on $31 Billion Watch Market: iQIYI, TNXP, REGRF, AITX; Leaders Report Latest Advances
AI Security, “Netflix of China”, Healthcare Breakthroughs, Pure Play on $31 Billion Watch Market: iQIYI, TNXP, REGRF, AITX; Leaders Report Latest Advances 
Via News Direct
Topics Artificial Intelligence
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Featured in Post Discussing Nonaddictive Painkillers Designed to Counter Opioid Crisis
Via Investor Brand Network
News headline image
The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions
Via ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins Expert Panel at Long COVID, RECOVER TLC Workshop
Via Investor Brand Network
News headline image
AI Security, “Netflix of China”, Healthcare Breakthroughs, Pure Play on $31 Billion Watch Market: iQIYI, TNXP, REGRF, AITX; Leaders Report Latest Advances
AI Security, “Netflix of China”, Healthcare Breakthroughs, Pure Play on $31 Billion Watch Market: iQIYI, TNXP, REGRF, AITX; Leaders Report Latest Advances 
Via News Direct
Topics Artificial Intelligence
News headline image
What's Going On With Tonix Pharmaceuticals Stock Friday? ↗
Tonix shares are trading higher Friday after the company announced the United States Patent and Trademark Office granted a patent covering the subcutaneous delivery of Zembrace Symtouch for treating... 
Via Benzinga
Topics Intellectual Property
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) Receives New US Patent for Subcutaneous Administration of Zembrace(R) SymTouch(R) to Treat Migraines
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.